Introduction
It is now established that people with erythrocyte glucose-6-phosphate dehydrogenase (GPD) deficiency may develop an acute haemolytic state after exposure to certain drugs, chemicals, or infections.1-3 Many drugs have been incriminated and some are commonly used-for example, acetylsalicylic acid, nitrofurantoin, sulphonamides, streptomycin, isoniazid, and paraaminosalicylic acid (PAS). These data have come from two sources: (a) controlled studies in which drugs were given to GPD-deficient volunteers or 5'Cr-labelled GPD-deficient red cells were transfused into normal recipients receiving the test drugs, and (b) case reports of patients who developed haemolytic anaemia after receiving drugs given for various illnesses. The second type of data, although useful, is more difficult to interpret as the illness itself may have provoked haemolysis, and in many cases more than one drug had been taken.
About 5 5°, of southern Chinese men have GPD deficiency,4 and in these subjects severe haemolysis leading to death may occur.5 Most controlled studies of drug-induced haemolysis in GPD deficiency have been carried out in Negroes with the GPD A(-) variant, which is a less severe defect and qualitatively different from that found in Chinese.7 Our aim was to determine more precisely the haemolytic effect of certain common drugs in people with severe GPD deficiency-in this case GPD-deficient Chinese, in whom the enzyme level is relatively low.
had GPD Canton, three had GPD B(-)Chinese, and two had GPD Hong Kong-Pokfulam (table I) . In three, simultaneous di-isopropylphosphofluoridate (DF32P) label8 was also used. These observations were carried out with the patient in the steady state-that is, when there were no changes in the packed cell volume or reticulocyte count.
For cross-tranfusion studies GPD deficient erythrocytes were labelled with "Cr and transfused into compatible (by in-saline agglutination and indirect antiglobulin test) GPD-normal male recipients. Informed consent was obtained from each recipient. After 5-10 days the drug under test was started and continued for 7-10 days. In five cases the effect of the drug on autologous 5"Cr-labelled red cells was tested in GPD-deficient individuals. These drugs-chloramphenicol (in two studies), streptomycin, isoniazid and PAS (two studies), and levodopa-had previously been shown not to be haemolytic by the cross-transfusion technique. The percentage of circulating 5"Cr-labelled erythrocytes was plotted against time on a semilogarithmic scale and the half life determined by extrapolating the corresponding parts of the curve before and after drug admninistration. 9 Fig 1 shows an example in which the "lCr half life was 35 days before the drug and three days after primaquine 30 mg/day.
Standard haematological techniques were used throughout.10 The methods used in studying red cell survival have been described.' 
Patients and methods
All subjects studied were southern Chinese. In this population GPD deficient variants are heterogeneous,7 and red-cell enzyme activity varies from 0 to 22 5'0 of normal.
Autologous red-cell survival using radioactive sodium chromate (5"Cr) as a label, was determined in 10 GPD-deficient subjects: five Results Table I shows the autologous red-cell survival of GPD-deficient erythrocytes in the steady state. The 5"Cr half life varied from 19 to 28 days (normal: mean (± SD) 28-2+2 8 days; range 24-33 days) and DF32P studies showed a shortening of the mean cell life to 54-85 days (normal: mean 113-5±30-6 days; range 84-5-145-4 days). The haemoglobin level of these subjects varied from 12 to 16 g/dl and the packed cell volume from 38% to 49%. There was no difference among the three deficient variants. The calculated 5"Cr elution rates using the DF32P results were 1-0-1-4% per day (normal-1 40±0-34% per day). centration often drops below 6 g/dl, and deaths have occured after haemoglobinuria and acute renal failure.5 6 Many drugs, many commonly used, have been reported to provoke acute haemolysis in GPD-deficient subjects. These drugs should therefore not be given to such people. In any given case, however, it is often difficult to determine whether a drug or some other factor was the provoking factor. For example, a GPD-deficient patient suffering from typhoid fever who has received co-trimoxazole and aspirin may have an attack of severe haemolysis caused by the infection itself I 15 or either one of the drugs. Their effects may also be additive. The use of cross-transfusion techniques to determine the survival of GPDdeficient red cells before and after drug administration has helped to define more clearly the haemolytic effect of drugs. In patients with typhoid fever we have shown that the infection rather than the chloramphenicol shortened the survival of GPD-deficient red cells."' Our present results show that primaquine, nitrofurantoin, aspirin in large doses, and sulphonamides aggravated haemolysis in GPD-deficient Chinese, whereas many other drugs (table II) did not. This knowledge is of obvious practical importance. It is noteworthy that the first-line anti-tuberculous drugs-streptomycin, isoniazid, and PAS-were not haemolytic for GPD-deficient cells, nor was levodopa in doses of up to 3 g/day. Furthermore, levodopa is not haemolytic in GPDdeficient Sardinians.i6 These observations do not support the hypothesis that favism, which is found in Mediterranean and Chinese people, is due to the levodopa content of fava beans.'7 Another factor that can determine the susceptibility of GPDdeficient red cells is the GPD variant itself. Mutant enzymes may react to haemolytic agents in different ways. Factors such as the "physiological" enzyme level in red cells and certain other biochemical characteristics seem to be important.'8 For example, while chloramphenicol does not shorten the survival of red cells in those with GPD Canton, GPD B(-) Chinese (present study), or GPD (A-),'9 it has been reported to do so in subjects with GPD Mediterranean.'0
The results with co-trimoxazole also suggest that people with the same GPD variant may react differently because of variations in the metabolism of the drug. This may be the result of coexisting disease that alters liver or renal function or some as yet undefined biochemical or metabolic characteristic.
The list of agents that can provoke acute haemolysis in GPDdeficient subjects will probably grow. Reports based only on clinical observations must be accepted with reservation, and studies with techniques similar to those we have used will help to define the haemolytic effect of drugs more accurately. 
Summary
In a double-blind study in six subjects propranolol significantly reduced the respiratory sensitivity to carbon dioxide rebreathing. This effect seems to have been due to beta-adrenergic blockade, since it was not seen with D-propranolol. In two subjects increasing doses of propranolol caused progressive reductions in respiratory sensitivity to values below normal and similar to those of patients with ventilatory failure. These changes are probably due to a central action of propranolol.
Introduction Beta-adrenergic blocking drugs may have deleterious effects in asthmatic patients owing to blockade of endogenous sympathetic drive to bronchial smooth muscle.1-3 In contrast, stimulation of beta-adrenergic receptors relaxes bronchial smooth muscle and also stimulates ventilation.4-7 During recent studies of the effects of propranolol on exercise we noticed a decrease in the ventilatory response in normal subjects. We therefore examined the effect of propranolol on the response to carbon dioxide rebreathing as this correlates well with the ventilatory response to exercise8 but is easier to measure.
We measured both the ventilatory and the maximum rate of inspiratory pressure development (dP/dtmax) responses to hypercapnia. 9 The latter measurement is a function of the initial contraction of the respiratory muscles and occurs before any significant flow of gas begins. To separate the beta-adrenergic blocking properties of propranolol from its other actions we examined the effects of both the commercially available racemic mixture (DLpropranolol) and the dextrorotatory isomer (D-propranolol). The latter has only 1/60th of the beta-adrenergic blocking function of the racemic mixture'5 but has similar membrane-stabilising activity.
Patients and methods
Six healthy volunteers aged 22-35 took part. None were receiving regular medication nor was there any previous history of asthma.
Carbon dioxide rebreathing was performed according to the method of Read'6 as modified by Matthews and Howell.9 Progressive hypercapnia was produced by rebreathing mixtures of 5% CO2 in oxygen.
Ventilation was determined by displacing air from a bag in bottle arrangement. A manometer line placed at the mouth was used to detect pressure changes and the signal was electronically differentiated to give dP/dtmax for each breath. End tidal CO2 levels were recorded throughout using a Godart Capnograph and were allowed to increase up to values of 9-10%.
Regressions of ventilatory and dP/dtmax responses on end tidal Pco, were calculated by the method of least squares. All were highly linear at high CO2 levels (r > 0 9). The slope of the lines was taken as a measure of sensitivity to CO,. The slopes and x-intercept values of the extrapolated line were compared by Wilcoxon's signed-ranks test for paired data.
Spirometry was performed before and after drug administration.
FIRST STUDY
The effects of DL-propranolol (80 mg) and an identical placebo were compared in a double-blind study. The CO, responses were determined on separate days, two hours after oral administration of the tablets in the fasting state. On another occasion two of the subjects had repeated doses of propranolol (40, 40, and 80 mg) every two hours to establish a dose-response relation. Venous blood samples were taken after each series ofrespiratory response measurements and plasma concentrations were estimated fluorometrically using the method of Shand et al. '7 
